{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:22:22Z","timestamp":1790284942680,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH\/NIDDK","award":["DK058404-11"],"award-info":[{"award-number":["DK058404-11"]}]},{"name":"NIH\/NIDDK","award":["DK058404-11"],"award-info":[{"award-number":["DK058404-11"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA095103"],"award-info":[{"award-number":["P50CA095103"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 096625"],"award-info":[{"award-number":["CA 096625"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00428-017-2093-3","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T10:32:36Z","timestamp":1487327556000},"page":"545-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous"],"prefix":"10.1007","volume":"470","author":[{"given":"Mongkon","family":"Charoenpitakchai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Jae","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Hande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanjuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"2093_CR1","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/0024-3205(95)02082-T","volume":"57","author":"YC Patel","year":"1995","unstructured":"Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB (1995) The somatostatin receptor family. Life Sci 57:1249\u20131265","journal-title":"Life Sci"},{"key":"2093_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1046\/j.1365-2362.1997.1740719.x","volume":"27","author":"P Jais","year":"1997","unstructured":"Jais P, Terris B, Ruszniewski P, LeRomancer M, Reyl-Desmars F, Vissuzaine C, Cadiot G, Mignon M, Lewin MJ (1997) Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Investig 27:639\u2013644","journal-title":"Eur J Clin Investig"},{"key":"2093_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","volume":"440","author":"M Papotti","year":"2002","unstructured":"Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G (2002) Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461\u2013475","journal-title":"Virchows Arch"},{"key":"2093_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1172\/JCI117090","volume":"93","author":"A Kubota","year":"1994","unstructured":"Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321\u20131325","journal-title":"J Clin Invest"},{"key":"2093_CR5","first-page":"3455","volume":"54","author":"JC Reubi","year":"1994","unstructured":"Reubi JC, Schaer JC, Waser B, Mengod G (1994) Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54:3455\u20133459","journal-title":"Cancer Res"},{"key":"2093_CR6","first-page":"3483","volume":"5","author":"N Kimura","year":"1999","unstructured":"Kimura N, Pilichowska M, Date F, Kimura I, Schindler M (1999) Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 5:3483\u20133487","journal-title":"Clin Cancer Res"},{"key":"2093_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","volume":"30","author":"JC Reubi","year":"2003","unstructured":"Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781\u2013793","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2093_CR8","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1006\/bbrc.1994.2054","volume":"202","author":"S Kagimoto","year":"1994","unstructured":"Kagimoto S, Yamada Y, Kubota A, Someya Y, Ihara Y, Yasuda K, Kozasa T, Imura H, Seino S, Seino Y (1994) Human somatostatin receptor, SSTR2, is coupled to adenylyl cyclase in the presence of Gi alpha 1 protein. Biochem Biophys Res Commun 202:1188\u20131195","journal-title":"Biochem Biophys Res Commun"},{"key":"2093_CR9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"IM Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934\u2013959","journal-title":"Cancer"},{"key":"2093_CR10","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evan DB (2008) One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063\u20133072","journal-title":"J Clin Oncol"},{"key":"2093_CR11","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Ruszniewski P (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:1556\u20131557","journal-title":"N Engl J Med"},{"key":"2093_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2265.1989.tb00436.x","volume":"30","author":"D Wynick","year":"1989","unstructured":"Wynick D, Anderson JV, Williams SJ, Bloom SR (1989) Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol 30:385\u2013388","journal-title":"Clin Endocrinol"},{"key":"2093_CR13","first-page":"5969","volume":"50","author":"JC Reubi","year":"1990","unstructured":"Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, Reading CC, Moertel C (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50:5969\u20135977","journal-title":"Cancer Res"},{"key":"2093_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.7326\/0003-4819-107-2-162","volume":"107","author":"LK Kvols","year":"1987","unstructured":"Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O'Connell MJ, Hahn RG (1987) Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 107:162\u2013168","journal-title":"Ann Intern Med"},{"key":"2093_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJM198609113151102","volume":"315","author":"LK Kvols","year":"1986","unstructured":"Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663\u2013666","journal-title":"N Engl J Med"},{"key":"2093_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1188\/12.CJON.56-64","volume":"16","author":"NM Gardner-Roehnelt","year":"2012","unstructured":"Gardner-Roehnelt NM (2012) Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects. Clin J Oncol Nurs 16:56\u201364","journal-title":"Clin J Oncol Nurs"},{"key":"2093_CR17","first-page":"761","volume":"32","author":"M Laznicek","year":"2012","unstructured":"Laznicek M, Laznickova A, Maecke HR (2012) Receptor affinity and preclinical biodistribution of radiolabeled somatostatin analogs. Anticancer Res 32:761\u2013766","journal-title":"Anticancer Res"},{"key":"2093_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273\u2013282","journal-title":"Eur J Nucl Med"},{"key":"2093_CR19","first-page":"2561","volume":"56","author":"ET Janson","year":"1996","unstructured":"Janson ET, Gobl A, Kalkner KM, Oberg K (1996) A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 56:2561\u20132565","journal-title":"Cancer Res"},{"key":"2093_CR20","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/0024-3205(91)90053-E","volume":"49","author":"WH Bakker","year":"1991","unstructured":"Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, Kooij PP, Bruns C, van Hagen PM, Marbach P et al (1991) In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 49:1593\u20131601","journal-title":"Life Sci"},{"key":"2093_CR21","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"EP Krenning","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716\u2013731","journal-title":"Eur J Nucl Med"},{"key":"2093_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2967\/jnumed.110.084236","volume":"52","author":"HR Maecke","year":"2011","unstructured":"Maecke HR, Reubi JC (2011) Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 52:841\u2013844","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"2093_CR23","doi-asserted-by":"publisher","first-page":"42S","DOI":"10.2967\/jnumed.110.085753","volume":"52","author":"V Ambrosini","year":"2011","unstructured":"Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR (2011) Radiopeptide imaging and therapy in Europe. J Nucl Med 52(Suppl 2):42S\u201355S","journal-title":"J Nucl Med"},{"key":"2093_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","volume":"42","author":"G Treglia","year":"2012","unstructured":"Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V (2012) Diagnostic performance of gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42:80\u201387","journal-title":"Endocrine"},{"key":"2093_CR25","doi-asserted-by":"crossref","unstructured":"Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL, Jr., O'Dorisio TM, O'Dorisio MS, Menda Y, Muller-Brand J, Howe JR et al. (2016) Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors. Pancreas.","DOI":"10.1097\/MPA.0000000000000734"},{"key":"2093_CR26","volume-title":"The impact of radiological response to peptide receptor radionuclide therapy on overall survival in patients with metastatic midgut neuroendocrine tumors","author":"M Yalchin","year":"2016","unstructured":"Yalchin M, Oliveira A, Theocharidou E, Pencharz D, Navalkissoor S, Quigley AM, Walker M, Caplin M, Toumpanakis C (2016) The impact of radiological response to peptide receptor radionuclide therapy on overall survival in patients with metastatic midgut neuroendocrine tumors. Clin Nucl Med."},{"key":"2093_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1309\/AJCPQ55SKOCYFZHN","volume":"143","author":"C Shi","year":"2015","unstructured":"Shi C, Gonzalez RS, Zhao Z, Koyama T, Cornish TC, Hande KR, Walker R, Sandler M, Berlin J, Liu EH (2015) Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. Am J Clin Pathol 143:398\u2013404","journal-title":"Am J Clin Pathol"},{"key":"2093_CR28","first-page":"187","volume":"5","author":"D Kaemmerer","year":"2013","unstructured":"Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP, Prasad V, Hommann M (2013) Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol 5:187\u2013194","journal-title":"Int J Clin Exp Pathol"},{"key":"2093_CR29","first-page":"4971","volume":"7","author":"K Daniel","year":"2014","unstructured":"Daniel K, Maria A, Amelie L, Isabell L, Stefan S, Luisa P, Merten H, Vikas P, Gerd B, Paul BR (2014) Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation. Int J Clin Exp Pathol 7:4971\u20134980","journal-title":"Int J Clin Exp Pathol"},{"key":"2093_CR30","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/modpathol.3800954","volume":"20","author":"M Volante","year":"2007","unstructured":"Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172\u20131182","journal-title":"Mod Pathol"},{"key":"2093_CR31","unstructured":"Team R R: A language and environment for statistical computing. (3.3):Vienna, Austria."},{"issue":"Suppl 1","key":"2093_CR32","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1530\/ERC-11-0013","volume":"18","author":"G Kloppel","year":"2011","unstructured":"Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl 1):S1\u201316","journal-title":"Endocr Relat Cancer"},{"key":"2093_CR33","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1158\/0008-5472.CAN-13-1199","volume":"73","author":"P Heidari","year":"2013","unstructured":"Heidari P, Wehrenberg-Klee E, Habibollahi P, Yokell D, Kulke M, Mahmood U (2013) Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization. Cancer Res 73:6865\u20136873","journal-title":"Cancer Res"},{"key":"2093_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ecl.2010.12.006","volume":"40","author":"G Nicolas","year":"2011","unstructured":"Nicolas G, Giovacchini G, Muller-Brand J, Forrer F (2011) Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin N Am 40:187\u2013204 ix-x","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2093_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.diii.2013.07.006","volume":"95","author":"MO Oksuz","year":"2014","unstructured":"Oksuz MO, Winter L, Pfannenberg C, Reischl G, Mussig K, Bares R, Dittmann H (2014) Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging 95:289\u2013300","journal-title":"Diagn Interv Imaging"},{"key":"2093_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1053\/j.semnuclmed.2009.10.004","volume":"40","author":"DJ Kwekkeboom","year":"2010","unstructured":"Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 40:78\u201388","journal-title":"Semin Nucl Med"},{"key":"2093_CR37","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/cncr.28760","volume":"121","author":"A Frilling","year":"2015","unstructured":"Frilling A, Clift AK (2015) Therapeutic strategies for neuroendocrine liver metastases. Cancer 121:1172\u20131186","journal-title":"Cancer"},{"key":"2093_CR38","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800\u2013816","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2093_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000371804","volume":"101","author":"M Korner","year":"2015","unstructured":"Korner M, Waser B, Reubi JC (2015) Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors? Neuroendocrinology 101:45\u201357","journal-title":"Neuroendocrinology"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-017-2093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-017-2093-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-017-2093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T13:25:42Z","timestamp":1589635542000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-017-2093-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2093"],"URL":"https:\/\/doi.org\/10.1007\/s00428-017-2093-3","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]},"assertion":[{"value":"19 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by the Vanderbilt Institutional Review Board. Consent was not required for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was partially supported by NIH\/NIDDK DK058404-11 (ZZ and TK), NIH\/NCI P50CA095103 (CS), and NCI CA 096625 (EL).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}